APA (7th ed.) Citation

Han, C., Keystone, E., Fleischmann, R., Smolen, J., Emery, P., Genovese, M., . . . Hsia, E. (2012). PMS52 Validation of Remission of Rheumatoid Arthritis by Traditional Disease Activity Score and Provisional Criteria by American College of Rheumatology and European League Agaisnt Rheumatism: Analysis Based on Patient Reported Outcomes from 3 Phase III Clinical Trials of Golimumab. Value in Health, A43. https://doi.org/10.1016/j.jval.2012.03.241

Chicago Style (17th ed.) Citation

Han, C., E. Keystone, R. Fleischmann, J.S Smolen, P. Emery, M. Genovese, M. Doyle, and E. Hsia. "PMS52 Validation of Remission of Rheumatoid Arthritis by Traditional Disease Activity Score and Provisional Criteria by American College of Rheumatology and European League Agaisnt Rheumatism: Analysis Based on Patient Reported Outcomes from 3 Phase III Clinical Trials of Golimumab." Value in Health 2012: A43. https://doi.org/10.1016/j.jval.2012.03.241.

MLA (9th ed.) Citation

Han, C., et al. "PMS52 Validation of Remission of Rheumatoid Arthritis by Traditional Disease Activity Score and Provisional Criteria by American College of Rheumatology and European League Agaisnt Rheumatism: Analysis Based on Patient Reported Outcomes from 3 Phase III Clinical Trials of Golimumab." Value in Health, 2012, p. A43, https://doi.org/10.1016/j.jval.2012.03.241.